IKK epsilon Antibody
Code | Size | Price |
---|
PSI-2329-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-2329-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
IKK epsilon Antibody: IKKE, IKKI, IKK-E, IKK-i, IKKE, KIAA0151, Inhibitor of nuclear factor kappa-B kinase subunit epsilon, Inducible I kappa-B kinase, I-kappa-B kinase epsilon
Application Note:
WB: 1-2 μg/mL; IHC: 10 μg/mL; IF: 20 μg/mL.
Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human samples; Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human samples; Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
IKK epsilon Antibody: Nuclear factor kappa B (NF-κB) is a ubiquitous transcription factor and an essential mediator of gene expression during activation of immune and inflammatory responses. NF-κB mediates the expression of a great variety of genes in response to extracellular stimuli. NF-κB is associated with IκB proteins in the cell cytoplasm, which inhibit NF-κB activity. IκB is phosphorylated by IκB kinase (IKK) complex that contains IKKα, IKKβ, and IKKγ. A novel molecule in the IKK complex was recently identified and designated IKKε/IKK-i. IKK epsilon is required for the activation of NF-κB by PMA and T cell receptors but not by TNFα and IL-1. IKKε/IKK-i message is expressed in a variety of tissues and is inducible by TNFα, IL-1, and LPS.
Background References:
- Peters et al. Mol Cell 2000;5(3):513-22.
- Shimada et al. Int Immunol 1999;11(8):1357-62 (WD0101).
Buffer:
IKK epsilon Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/ml
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (75%)
Immunogen:
Anti-IKK epsilon antibody (2329) was raised against a peptide corresponding to 16 amino acids near the carboxy terminus of human IKK epsilon.
The immunogen is located within the last 50 amino acids of IKK epsilon.
The immunogen is located within the last 50 amino acids of IKK epsilon.
ISOFORMS:
Human IKK epsilon has 2 isoforms, including isoform 1 (716aa, 80kD) and isoform 2 (631aa, 70kD). Mouse IKK epsilon has one isoform (717aa, 81kD) and Rat IKK epsilon also has one isoform (717aa, 80kD). 2329 can detect human, mouse and possibly rat.
NCBI Gene ID #:
9641
NCBI Official Name:
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon
NCBI Official Symbol:
IKBKE
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 80kD
Observed: 80 kD
Observed: 80 kD
Protein Accession #:
AF241789
Protein GI Number:
7288877
Purification:
IKK epsilon Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
SPECIFICITY:
It has no cross response to IKKa, IKKb, or IKKy.
Swissprot #:
Q14164
User NOte:
Optimal dilutions for each application to be determined by the researcher.
VALIDATION:
Induced Expression Validation (Figure 1): Raw 264.7 cells were treated with LPS (0.3 µg /mL) for different time period (3 hrs and 6 hrs). IKK epsilon expression detected by anit-IKK epsilon antibodies (2329) was induced by LPS treatment and the expression levels were increased gradually at 3 hrs and 6 hrs.
Related Products
Product Name | Product Code | Supplier | IKK epsilon Peptide | PSI-2329P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|